Efficacy of probing the nasolacrimal duct with adjunctive Mitomycin-C for epiphora in adults.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 11772600.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To investigate the efficacy and safety of adjunctive low-dose mitomycin-C during lacrimal probing for adults with blocked nasolacrimal ducts. Prospective, noncomparative, interventional case series. From January 1998 to December 2000, a total of 32 adult patients (36 eyes) seen with epiphora caused by primary nasolacrimal duct obstruction was treated and evaluated. Lacrimal probing with adjunctive mitomycin-C (0.2 mg/ml). Objective evaluation of patency with irrigation, as well as patients' subjective assessment of improvement. For 32 of the treated eyes (89%), the nasolacrimal duct remained open 9 months after treatment. Repeat procedure was successful for two of the remaining four eyes with recurrent obstruction during follow-up, yielding an overall patency rate of 94%. Patient satisfaction was assessed after 9 months and indicated that the epiphora was at least mildly improved for 30 (83%) of the treated eyes. Watering was completely absent for nine eyes (25%), rated as moderately improved for 17 (47%), and mildly improved for 4 (11%). No complications were encountered over the 9-month follow-up period. Our experience suggests good long-term results for probing with adjunctive, topical Mitomycin-C for cases of adult epiphora caused by obstruction of the nasolacrimal duct followed by repeat procedure if necessary. It can be recommended as a simple, effective, and minimally invasive technique, with no significant complications resulting from low-dose use in our study.
Medical subject headings
- Antibiotics, Antineoplastic
- Dacryocystorhinostomy
- Lacrimal Duct Obstruction
- Mitomycin
- Nasolacrimal Duct